Lab
Devansh Lab Werks,inc
Devansh Lab Werks,inc was paid $5.91M by Medicaid between Oct 2018 and Dec 2024, across 127 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 26% of everything it billed.
33Billing provider infoDEVANSH LAB WERKS,INC
HOMEWOOD, AL 35209
HOMEWOOD, AL 35209
33aNPI1841798667assigned 01/26/2018
33bProvider typeClinical Medical Laboratory
28Total paid$5.91M
24GClaims429,359
24DCodes billed127
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Alabama
Rank by total paid#11 of 61
Median peer was paid$46K
This provider vs. median130×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65 | $0.00 | |
| 2019 | 18,082 | $39K | |
| 2020 | 42,810 | $657K | |
| 2021 | 114,102 | $1.82M | |
| 2022 | 134,505 | $1.72M | |
| 2023 | 78,590 | $1.18M | |
| 2024incomplete | 41,205 | $505K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 26% | 28,975 | 23,656 | $1.54M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 13% | 9,355 | 5,966 | $793K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 9.9% | 7,453 | 5,130 | $586K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.3% | 23,017 | 16,580 | $430K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5.3% | 20,554 | 16,798 | $310K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.8% | 2,579 | 2,286 | $226K |
| 87500 | 3.4% | 19,945 | 4,563 | $200K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.3% | 7,498 | 6,059 | $192K |
| 87481 | 2.3% | 6,399 | 4,835 | $135K | |
| 87150 | 1.9% | 6,158 | 3,815 | $114K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.5% | 3,343 | 2,524 | $90K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 2,260 | 1,482 | $78K |
115 more codes
| 87640 | 1.2% | 7,197 | $68K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 8,672 | $66K |
| 87653 | 1.1% | 6,425 | $63K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 877 | $61K |
| 87641 | 1.0% | 6,050 | $60K | |
| 80050 | General health panel | <1% | 3,986 | $54K |
| 80061 | Lipid panel | <1% | 10,688 | $37K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,561 | $33K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,777 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,296 | $31K |
| 80336 | <1% | 5,838 | $26K | |
| 80323 | <1% | 5,023 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,908 | $24K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,286 | $24K |
| 80356 | <1% | 6,406 | $24K | |
| 80361 | <1% | 6,685 | $23K | |
| 80346 | <1% | 6,678 | $23K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,082 | $22K |
| 80348 | <1% | 6,680 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,657 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,846 | $20K |
| 80354 | <1% | 6,627 | $20K | |
| 80324 | <1% | 6,657 | $18K | |
| 80359 | <1% | 6,487 | $17K | |
| 80358 | <1% | 6,675 | $17K | |
| 80371 | <1% | 6,423 | $16K | |
| 80355 | <1% | 6,163 | $16K | |
| 80365 | <1% | 6,667 | $16K | |
| 82607 | <1% | 4,234 | $15K | |
| 80353 | <1% | 6,643 | $15K | |
| 80360 | <1% | 6,422 | $15K | |
| 80349 | <1% | 5,609 | $15K | |
| 80366 | <1% | 6,070 | $14K | |
| 80370 | <1% | 5,817 | $13K | |
| 80367 | <1% | 5,874 | $13K | |
| 80372 | <1% | 6,362 | $13K | |
| 80364 | <1% | 5,156 | $13K | |
| 80373 | <1% | 6,467 | $13K | |
| 80345 | <1% | 4,521 | $12K | |
| 83992 | <1% | 6,537 | $11K | |
| 84439 | <1% | 4,838 | $11K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 629 | $10K |
| 87486 | <1% | 1,146 | $10K | |
| 86003 | <1% | 92 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 356 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,320 | $9K |
| 87581 | <1% | 1,153 | $8K | |
| 87541 | <1% | 1,153 | $8K | |
| 80368 | <1% | 5,710 | $8K | |
| 80074 | <1% | 664 | $6K | |
| 84153 | <1% | 1,083 | $5K | |
| 86480 | <1% | 111 | $5K | |
| 80363 | <1% | 1,326 | $5K | |
| 87799 | <1% | 418 | $5K | |
| 81226 | <1% | 110 | $4K | |
| 87532 | <1% | 605 | $4K | |
| 83550 | <1% | 2,013 | $4K | |
| 86141 | <1% | 1,050 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 410 | $3K |
| 83540 | <1% | 2,031 | $3K | |
| 81225 | <1% | 98 | $3K | |
| 84550 | <1% | 1,922 | $2K | |
| 82627 | <1% | 338 | $2K | |
| 87563 | <1% | 156 | $2K | |
| 82670 | <1% | 285 | $2K | |
| 81001 | <1% | 3,017 | $2K | |
| 81227 | <1% | 98 | $2K | |
| 84154 | <1% | 352 | $2K | |
| 80321 | <1% | 650 | $2K | |
| 87631 | <1% | 78 | $2K | |
| 81401 | <1% | 98 | $2K | |
| 80164 | <1% | 419 | $1K | |
| 81328 | <1% | 96 | $1K | |
| 81335 | <1% | 96 | $1K | |
| 81230 | <1% | 98 | $1K | |
| 81231 | <1% | 96 | $1K | |
| 82043 | <1% | 715 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 779 | $1K |
| 84144 | <1% | 215 | $1K | |
| 81291 | <1% | 180 | $1K | |
| 86431 | <1% | 615 | $1K | |
| 86635 | <1% | 36 | $953.08 | |
| 82785 | <1% | 55 | $826.20 | |
| 81241 | <1% | 96 | $798.26 | |
| 84480 | <1% | 173 | $798.00 | |
| 86780 | <1% | 216 | $734.81 | |
| 81355 | <1% | 96 | $669.62 | |
| 84403 | <1% | 94 | $663.18 | |
| 81240 | <1% | 96 | $642.50 | |
| 80362 | <1% | 66 | $589.05 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 591 | $540.00 |
| 83735 | <1% | 382 | $494.00 | |
| 80076 | <1% | 371 | $488.90 | |
| 84481 | <1% | 69 | $488.72 | |
| 82746 | <1% | 336 | $429.00 | |
| 87340 | <1% | 117 | $418.53 | |
| 86803 | <1% | 112 | $396.12 | |
| 85652 | <1% | 192 | $349.69 | |
| 86769 | <1% | 17 | $306.74 | |
| 82728 | <1% | 305 | $289.02 | |
| 86038 | <1% | 26 | $255.50 | |
| 84100 | <1% | 127 | $135.84 | |
| 83525 | <1% | 50 | $125.60 | |
| 86709 | <1% | 35 | $125.26 | |
| 80335 | <1% | 33 | $116.92 | |
| 83970 | <1% | 14 | $108.18 | |
| 84436 | <1% | 55 | $86.04 | |
| 85610 | <1% | 63 | $71.07 | |
| 80178 | <1% | 32 | $30.88 | |
| 83690 | <1% | 22 | $28.95 | |
| 85384 | <1% | 12 | $25.12 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,867 | $11.95 |
| 82248 | <1% | 32 | $10.96 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,837 | $2.20 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 550 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKANCHARLA, SUDHAKAR (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Microgen Health, INC | Chantilly, VA | $2.14M |
| Devansh Lab Werks,inc | Irving, TX | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.